July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study
Author Affiliations & Notes
  • Fatma Zaguia
    McGill University, Montreal, Quebec, Canada
  • Michael Ross
    McGill University, Montreal, Quebec, Canada
  • Mash Darvish
    McGill University, Montreal, Quebec, Canada
  • Jean Deschenes
    McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Fatma Zaguia, None; Michael Ross, None; Mash Darvish, None; Jean Deschenes, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3659. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fatma Zaguia, Michael Ross, Mash Darvish, Jean Deschenes; Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3659. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Bacterial keratitis is a serious ocular problem that can, if not appropriately treated, lead to corneal scarring, perforation, endophthalmitis, and ultimately blindness. Current accepted treatment by most ophthalmologists for corneal ulcers involves aggressive therapy with fortified antibiotics typically every hour, round the clock dosing for at least the 48 hours, causing significant distress to patients, as well as compliance issues. Finally, delayed epithelial healing rate and conjunctival/corneal toxicity are known side effects of fortified antibiotics. Besifloxacin ophthalmic suspension is a novel topical fluoroquinolone, specifically developed as an ocular topical preparation. Several in vitro studies have shown a higher potency when compared with earlier fluoroquinolones, however there is limited data about its safety and efficacy in the treatment of bacterial keratitis.

Methods : Our study is a multi-site prospective, randomized trial to determine if besifloxacin when compared to fortified tobramycin/vancomycin drops results in non-inferior clinical resolution of bacterial keratitis. Patients with bacterial keratitis were randomized to receive besifloxacin at initially Q4H dosing vs Fortified Tobramycin + Vancomycin at initial Q1H dosing. Complete exams were recorded at initial visit, and at predetermined subsequent visits.

Results : Overall, there were no treatment failures in the besifloxacin group. Median number of days taken for the ulcer to heal between besifloxacin group (13 days) and fortified group (16 days) showed no statistical difference (p=0.5). The group treated with besifloxacin showed statistically significant more rapid epithelialization rate, at mean of 4 days vs 10(p=0.01).

Conclusions : Our preliminary results failed to find a difference in efficacy of besifloxacin, a novel fluoroquinolone in the treatment of bacterial keratitis when compared to traditional combination therapy of fortified antibiotics.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.